Vaccine - Approval - Furuncolosis & Vibriosis

Canadian approval for furuncolosis & vibriosis vaccine

Alpharma has received sales approval for the fish vaccine ALPHA JECT 4000 in Canada. The vaccine protects against furuncolosis, vibriosis and cold water vibriosis (also known as 'Hitra disease') in salmon.

"We are the first European vaccine manufacturers that have had a fish vaccine approved on the attractive Canadian aquaculture market," said Director Morten Nordstad.

Alpharma has also previously had fish vaccines in Canada, but these have been manufactured in the USA. ALPHA JECT 4000 is produced at Alpharma's facility in Overhalla, Nord-Trøndelag, Norway.

Alpharma has now received approval for its market-adapted fish vaccines in both Chile and Canada during the last four months.

The Canadian approval is important, and Alpharma can now offer fish vaccines in all the important salmon and trout markets and is better equipped to service global aquaculture players' needs," said Marketing Director Jan Oppen Berntsen.